Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum

Daratumumab, a monoclonal antibody therapeutic, is highly efficacious and widely used in all stages of multiple myeloma and amyloidosis and has promising activity in other hematologic disorders. Daratumumab interacts with red blood cells, interfering with pre-transfusion testing. This interference can lead to compromising transfusion safety, extensive blood bank work ups and delays in provision of compatible units. Several methods have been developed to negate daratumumab interference with indirect antiglobulin testing. They are based on i) standard blood bank techniques including dithiothreitol and enzymatic treatment of reagent cells, using reagent red blood cells negative for CD38, ii) blocking CD38 antigens on reagent or donor cells, iii) neutralization of anti-CD38 antibody in patient plasma prior to testing, and iv) extended antigen typing of patient red blood cells in conjunction with provision of phenotypically matched units for transfusion. Implementation of those methods by the blood bank should be a planned effort coordinated with the patient's clinical team. Timely involvement of blood bank and transfusion services and educational efforts by both blood banks and clinical providers can improve the overall daratumumab safety profile in regard to blood transfusion.

show abstract

“…A high affinity single-stranded DNA oligonucleotides, aptamers, specific to daratumumab can also be used to neutralize binding to CD38. 41 …”

Section: Methodologies To Negate Daratumumab Interference During Pre-transfusion Testingmentioning

confidence: 99%

Overcoming Drug Interference in Transfusion Testing: A Spotlight on Daratumumab

Nedumcheril¹,

DeSimone²,

Racine‐Brzostek³

et al. 2021

JBM

View full text Add to dashboard Cite

show abstract

“…In recent years, the emphasis on proactive healthcare diagnostics has steadily increased and shifted from reactive medical practices to preventative strategies [92][93][94][95][96][97]. Early disease prevention, a cornerstone of this movement, seeks to detect and address potential health issues even before they manifest as noticeable symptoms, where the current strides in the development of wearable devices equipped with TENGS hold great potential to revolutionize early disease prevention strategies by facilitating continuous, real-time health monitoring.…”

Section: Improving Disease Prevention Through Array Textile Designmentioning

confidence: 99%

Array-Designed Triboelectric Nanogenerator for Healthcare Diagnostics: Current Progress and Future Perspectives

Zhao,

Zhu,

Wang

et al. 2024

JLPEA

View full text Add to dashboard Cite

Array-designed triboelectric nanogenerators (AD-TENGs) have firmly established themselves as state-of-the-art technologies for adeptly converting mechanical interactions into electrical signals. Central to the AD-TENG’s prowess is its inherent modularity and the multifaceted, grid-like design that pave the way to robust and adaptable detection platforms for wearables and real-time health monitoring systems. In this review, we aim to elucidate the quintessential role of array design in AD-TENGs for healthcare detection, emphasizing its ability to heighten sensitivity, spatial resolution, and dynamic monitoring while ensuring redundancy and simultaneous multi-detection. We begin from the fundamental aspects, such as working principles and design basis, then venture into methodologies for optimizing AD-TENGs that ensure the capture of intricate physiological changes, from nuanced muscle movements to sensitive electronic skin. After this, our exploration extends to the possible cutting-edge electronic systems that are built with specific advantages in filtering noise, magnifying signal-to-noise ratios, and interpreting complex real-time datasets on the basis of AD-TENGs. Culminating our discourse, we highlight the challenges and prospective pathways in the evolution of array-designed AD-TENGs, stressing the necessity to refine their sensitivity, adaptability, and reliability to perfectly align with the exacting demands of contemporary healthcare diagnostics.

show abstract

“…Aptamers are single-stranded oligonucleotides with a three-dimensional structure giving high affinity towards a specific target ( Figure 2 b). They are usually isolated by enrichment of single-stranded oligonucleotide wide libraries and reproduced through conventional DNA-synthesis techniques [ 112 ]. Like nanobodies, aptamers are characterized by low immunogenicity, high penetration capacity/high selectivity towards targets, and major solubility.…”

Section: Overcoming the Newest: From The Microscopic To The Nanoscopi...mentioning

confidence: 99%

Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment

2022

View full text Add to dashboard Cite

Multiple myeloma is characterized by a wide clinical heterogeneity due to an intricate network of interactions between bone marrow-resident clonal plasma cells and the microenvironment. Over the last years, dramatic improvement in the understanding of these pathways led to the introduction of novel drugs with immune-mediated mechanisms of action. Some of these compounds, such as the anti-cd38 daratumumab and isatuximab, the anti-slamf-7 elotuzumab, and the antibody-drug conjugate belantamab-mafodotin, have been tested in large clinical trials and have now fully entered the real-life management. The bispecific T-cell engagers are under investigation with promising results, and other satisfactory data is expected from the application of nanotechnologies. The perfect timing to introduce these drugs in the sequence of treatment and their adverse events represent new challenges to be addressed, and further experience is required to improve their use.

show abstract

Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum

Cited by 8 publications

References 40 publications

Overcoming Drug Interference in Transfusion Testing: A Spotlight on Daratumumab

Overcoming Drug Interference in Transfusion Testing: A Spotlight on Daratumumab

Array-Designed Triboelectric Nanogenerator for Healthcare Diagnostics: Current Progress and Future Perspectives

Race for the Cure: From the Oldest to the Newest Monoclonal Antibodies for Multiple Myeloma Treatment

Contact Info

Product

Resources

About